Share

April 30, 2019; 92 (18) Null HypothesisOpen Access

INTREPAD

A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Pierre-François Meyer, Jennifer Tremblay-Mercier, Jeannie Leoutsakos, Cécile Madjar, Marie-Élyse Lafaille-Maignan, Melissa Savard, Pedro Rosa-Neto, Judes Poirier, Pierre Etienne, John Breitner, for the PREVENT-AD Research Group
First published April 5, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007232
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
1402

Share

This article has a correction. Please see:

Article Information

vol. 92 no. 18 e2070-e2080
DOI: 
https://doi.org/10.1212/WNL.0000000000007232
PubMed: 
30952794
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 1, 2018
  • Accepted in final form January 7, 2019
  • First Published April 5, 2019.

Article Versions

Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Pierre-François Meyer, MSc*,
    2. Jennifer Tremblay-Mercier, MSc*,
    3. Jeannie Leoutsakos, PhD,
    4. Cécile Madjar, MSc,
    5. Marie-Élyse Lafaille-Maignan, PhD,
    6. Melissa Savard, MSc,
    7. Pedro Rosa-Neto, MD, PhD,
    8. Judes Poirier, PhD†,
    9. Pierre Etienne, MD†,
    10. John Breitner, MD, MPH†;
    11. for the PREVENT-AD Research Group
  1. Pierre-François Meyer, MSc*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) Lazlo & Etelka Kollar fellowship, McGill University (2) Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jennifer Tremblay-Mercier, MSc*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jeannie Leoutsakos, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer Disease, Associate Editor, 2016-present (not compensated) PLOS One, Associate Editor, 2018-present (not compensated)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I serve on the NIDA Addictions IRB

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NAID, R01AI117065-01A1, Co-I, 2015-2019 NIA, R01AG046274, Co-I, 2014-2019 NIA, R01AG050515, Co-I, 2016-2021 NIDA, R01DA037314, Co-I, 2015-2020 NIH, Cornell Subcontract 16060870, Co-I, 2016-2021 NIA, R01AG057725, Co-I, 2017-2021 NIMH, R01MH115487, Co-I, 2018-2021 NIAAA, R01AA024101, Co-I, 2018-2023 NIDA, R01DA041367, Co-I, 2017-2022 NHLBI, R24HL111895, Co-I, 2016-2019 NIA, R21AG056721, Co-I, 2018-2020 NIA, K23AG044441, Co-I, 2014-2019 NIA, P30AG059298, Core Co-Leader, 2018-2023 CDC, R01CE003069, Co-I, 2018-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer's Association, 0266-2799-4609 , Co-I, 2015-2018 Stock/Stock Options, Medical Equipment & Materials: Merck, Rite Aid, Express Scripts Holding

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Cécile Madjar, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Marie-Élyse Lafaille-Maignan, PhD,
    6. Scientific Advisory Boards:

    1. (1) Clinical excellence committee on social services with a focus on youth, mental health and dependence for the Institut National d?excellence en sant? et en services sociaux (INESS). (2) International Market Access Consulting

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. McGill University

    Research Support, Foundations and Societies:

    1. Kollar Scholarship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Aphria, 2017-2018 (2) Illumina Inc, 2017-2018 (3) Google, 2017-2018 (4) GILEAD SCIENCES INC 2017-2018 (5) ALLERGAN PLC 2017-2018 (6) Baxter international inc 2017 (7) Celgene 2017 (8) NEUROTROPE 2017

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Melissa Savard, MSc,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Pedro Rosa-Neto, MD, PhD,
    8. Scientific Advisory Boards:

    1. (1) Enigma radiopharmaceutical (2) Kalgene

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. associate editor: Frontier in Aging Neurosciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Enigma pharmaceuticals (2) Eli-Lilly

    Research Support, Government Entities:

    1. (1) FRSQ, 35271, principal applicant, 2014-2018 (2) CIHR, 363444, co-applicant, 2016-2019 (3) CIHR, 366009, co-applicant, 2016-2020 (4) CIHR, 201312CNA-322265-CNA-CFAF-32054, co- investigator, 2014-2019

    Research Support, Academic Entities:

    1. (1) Merck, Sharpe & Dohme Corporation/McGill Faculty of Medicine Grant for Translational Research

    Research Support, Foundations and Societies:

    1. (1) Weston Brain Institute (2) Alzheimer's Association (3) Brain Canada CQDM

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Judes Poirier, PhD†,
    9. Scientific Advisory Boards:

    1. 1) Fondation Alzheimer (France)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor, 2017- 2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. Young and Centanarian, Tr?carr? (Canada), 2017 Alzheimer's Disease: The Complete Guide, 2012

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. J.L. Levesque Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Pierre Etienne, MD†,
    10. Scientific Advisory Boards:

    1. Ex-member of the Scientific Advisory Board of Sciformix, a consulting safety and risk management company based in Pune and Mumbai, India. Sciformix was acquired by Covance in 2018.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. John Breitner, MD, MPH†;
    11. Scientific Advisory Boards:

    1. (1) Mayo Clinic Studies on Aging, Scientific Advisory Board (NIH-funded program) (2) Data and Safety Monitoring Board, SPRINT-MIND clinical trial (NIA / NHLBI sponsor) (3) Consultant to Cerespir Pharmaceuticals

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Receive occasional honoraria for industry-sponsored talks

    Editorial Boards:

    1. Alzheimer's Disease and Associated Disorders, Editorial Board, 2003 - present; PLOS-One, Academics, 2009 - present; Alzheimer's and Dementia, Editorial Board, 2007 - present;

    Patents:

    1. NONE

    Publishing Royalties:

    1. Fast Facts - Dementia. Second Edition. Health Press, 2009 (no royalties received in over two years)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Cerespir, Inc (consultant)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research Support (gift) from Pfizer Canada

    Research Support, Government Entities:

    1. (1) Fonds de Recherche du Quebec - Sante PI 2012-2015

    Research Support, Academic Entities:

    1. (1) Program support from McGill University Faculty of Medicine

    Research Support, Foundations and Societies:

    1. (2) Research support from the Douglas Hospital Research Centre and the Douglas Hospital Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. for the PREVENT-AD Research Group
  1. From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.
  1. Correspondence
    Dr. Breitner john.breitner{at}mcgill.ca
View Full Text

Article usage

Article usage: April 2019 to July 2020

AbstractFullPdfSource
Apr 20191660417616Highwire
May 20191581026201Highwire
Jun 20197833684Highwire
Jul 20192024753Highwire
Aug 20191916742Highwire
Sep 20191010825Highwire
Oct 20192414050Highwire
Nov 2019208138Highwire
Dec 2019128534Highwire
Jan 2020914849Highwire
Feb 2020146827Highwire
Mar 2020119861Highwire
Apr 20201111845Highwire
May 20201310232Highwire
Jun 2020157126Highwire
Jul 202075819Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me